

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic or recurrent HER2-positive breast cancer
 - a. Used initially in combination with trastuzumab (required) and docetaxel (if tolerated)
 - b. **NOT** have a history of prior anti-HER2 therapy or chemotherapy for metastatic disease
2. Neoadjuvant treatment for HER2-positive locally advanced, inflammatory, or early stage breast cancer
 - a. Used in combination with trastuzumab and chemotherapy
 - b. Greater than 2 cm in diameter **OR** node positive
3. Adjuvant therapy for HER2-positive early stage breast cancer
 - a. Used in combination with trastuzumab and chemotherapy

AND ALL of the following:

- a. Females of childbearing potential should have pregnancy excluded before the start of treatment with Perjeta, prevented during therapy and for 7 months after treatment cessation
- b. Left ventricular ejection fraction (LVEF) is above 50%

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Metastatic or recurrent HER2-positive breast cancer

AND ALL of the following:

- a. Used in combination with trastuzumab (required) and docetaxel (if tolerated)
- b. Left ventricular ejection fraction (LVEF) is above 50%

Prior – Approval *Renewal* Limits

Same as above